Provided by Tiger Fintech (Singapore) Pte. Ltd.

Verastem

5.60
-0.2800-4.76%
Post-market: 5.770.1700+3.04%19:45 EDT
Volume:1.30M
Turnover:7.37M
Market Cap:307.72M
PE:-1.60
High:5.84
Open:5.78
Low:5.58
Close:5.88
Loading ...

Verastem reports Q1 adjusted EPS (79c), two estimates (77c)

TIPRANKS
·
14 May

Verastem Reports Increased Q1 2025 Net Loss of $52.1M and EPS of $0.96, Adjusted Net Loss of $42.9M

Reuters
·
14 May

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

THOMSON REUTERS
·
14 May

Verastem Q1 Basic EPS USD -0.96

THOMSON REUTERS
·
14 May

Verastem Q1 Net Income USD -52.103 Million

THOMSON REUTERS
·
14 May

Verastem’s Market Potential Boosted by Accelerated Approval of AVMAPKI FAKZYNJA for KRAS Mutant LGSOC

TIPRANKS
·
09 May

RBC Raises Price Target on Verastem to $16 From $14, Keeps Outperform, Speculative Risk

MT Newswires Live
·
09 May

Verastem Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
09 May

Verastem (VSTM) Gets a Buy from RBC Capital

TIPRANKS
·
09 May

BUZZ-Verastem climbs on FDA approval of ovarian cancer therapy

Reuters
·
09 May

Verastem’s Breakthrough FDA Approval and Market Potential for KRAS Mutant LGSOC Therapy

TIPRANKS
·
09 May

Verastem price target raised to $19 from $15 at Jefferies

TIPRANKS
·
09 May

Verastem trading resumes

TIPRANKS
·
09 May

Verastem Oncology Cancer Drug Combination Gets FDA Approval

Dow Jones
·
09 May

BRIEF-Verastem Says AVMAPKI FAKZYNJA Co-Pack Expected To Be Available For Adult Patients In U.S. In One Week

Reuters
·
09 May

Verastem- Avmapki Fakzynja Co-Pack Expected to Be Available for Adult Patients With Kras-Mutated Recurrent Lgsoc in U.S. in One Week

THOMSON REUTERS
·
09 May

FDA Grants Accelerated Approval to Verastem Inc.'s AVMAPKI FAKZYNJA CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Reuters
·
09 May

Verastem Receives US FDA Approval for Drug Combination to Treat Recurrent Ovarian Cancer

MT Newswires Live
·
09 May

U.S. FDA approves Verastem's cancer therapy

Reuters
·
09 May

BRIEF-FDA Grants Accelerated Approval To Combination Of Avutometinib And Defactinib For Kras-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Reuters
·
09 May